Compare Teradyne, Inc. (TER) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teradyne, Inc. vs Zoetis Inc — how do they compare? Teradyne, Inc. trades at $403 (market cap $62.34B), while Zoetis Inc trades at $74.76 (market cap $30.20B). The key difference: Teradyne, Inc. is far larger — about 2.1× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.9%). Which is the better fit depends on your goals — on Pluang, investors hold Teradyne, Inc. for 37 Days and Zoetis Inc for 70 Days on average.
| TER | ZTS | |
|---|---|---|
Market Cap | $62.34B | $30.20B |
Volume | 3,368,404 | 6,175,327 |
Sector | Technology | Health |
52-Week High | $483.84 | $147.53 |
52-Week Low | $132.05 | $69.09 |
Typical Hold Time | 37 Days | 70 Days |
Enterprise Value | $62.08B | $37.76B |
Dividend Yield | 0.13% | 2.9% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Teradyne (TER) trades at $402.68, down 2.21% on the day, but maintains a bullish technical outlook with strong support near $388. The company reported robust earnings beats in recent quarters, with Q2 2026 EPS of $2.47 surpassing the $2.09 estimate. Revenue growth is accelerating, projected to reach $4.5 billion in 2026, while net income margins are expected to expand to 25.76%. Recent developments include the launch of the Magnum E2 memory test system and Iris 100 for microLED devices, positioning TER to capitalize on AI and high-performance computing demand.
The investment outlook for TER is positive, driven by strong fundamentals, analyst optimism, and strategic positioning in semiconductor test equipment. Key opportunities include exposure to AI-driven demand and consistent earnings outperformance. Risks involve competitive pressures from firms like KLAC and COHU, cyclical semiconductor industry dynamics, and execution risks in new product launches. With a consensus price target of $461.50 and no sell ratings, Wall Street sentiment remains bullish, though valuation multiples are elevated.
Zoetis (ZTS) trades at $74.77, up 4.5% with strong profitability metrics including 71.67% gross margins and 27.69% net income margin. The stock shows mixed technical signals with bullish oscillators but bearish moving averages, trading near resistance at $75. Recent earnings show beats in Q4 2025 and Q2 2026 but a miss in Q1 2026, with Q3 2026 results pending. The company maintains robust cash flow generation despite competitive pressures in the U.S. companion animal market.
Zoetis presents a compelling value opportunity with a P/E of 11.92 below industry averages, though near-term headwinds from pet care weakness and competition persist. Analyst consensus targets $87.33 with no sell ratings, suggesting 17% upside potential. Key risks include ongoing margin pressure and market share challenges, but strong international growth and dividend sustainability support long-term bullish thesis.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
